Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT-1459
- Development stage
- Discontinued
- Lead developer
- Chugai Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
AT-1459 is a small molecule, orally active direct thrombin inhibitor (Ki = 4.9 nM) originally developed by JW C&C Research Lab (formerly C&C Research Laboratories, a joint venture between JW Pharmaceutical and Chugai Pharmaceutical). It was investigated as an antithrombotic agent for the prevention and treatment of venous and arterial thrombosis. In preclinical animal models of thrombosis, AT-1459 demonstrated potent antithrombotic efficacy with a rapid onset of action and a favorable bleeding profile compared to standard anticoagulants like argatroban and dalteparin. However, active clinical development of this compound has been discontinued.
02
Targets
F2 (Thrombin)
Beyond the preview
Go deeper on AT-1459.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT-1459.